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Two affected and one unaffected siblings from a French-Canadian family were evaluated in our neurogenetic clinic.
The oldest brother had intentional and postural hand tremor while his youngest sister presented mild ataxia, a similar
hand tremor and global developmental delay. Brain MRIs of the two affected family members further revealed a
significant cerebellar atrophy. For this study we conducted a whole exome sequencing (WES) investigation using
genomic DNA prepared from the affected brother and sister, alongside DNA prepared from their unaffected mother,
and identified two mutations previously reported to cause a rare disorder known as Congenital Disorder of Glycosylation,
type Ia (CDG1A) (OMIM #212065). This study emphasizes how the diagnosis of patients presenting a mild tremor
phenotype associated with cerebellar atrophy may benefit from WES in establishing genetic defects associated
with their conditions.
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The hereditary cerebellar ataxias are a clinically and genet-
ically heterogeneous group of disorders, where the cere-
bellum is predominantly affected. The classification of
spinocerebellar ataxias has been a subject of debate for
several years and in 1988 Harding proposed a first order-
ing [1]. Since the advent of high-throughput sequencing
technologies, prodigious advances have been made in hu-
man genetics and the classification and management of
hereditary cerebellar ataxias has also been transformed
[2]. To date, mutations in numerous genes are known to
cause cerebellar ataxias, where S. Jayadev and T.D. Bird
recently published a nice overview of hereditary ataxias
[3]. Dominant forms can be explained by defects in 35 dif-
ferent genes (SCAs), where many of them are caused by a
CAG coding expansion. For the other SCAs, expansions
in non-coding regions, point mutations and small inser-
tions/deletions are found. For the recessives forms less* Correspondence: nicolas.dupre.cha@ssss.gouv.qc.ca
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unless otherwise stated.genes are known to cause cerebellar ataxia. Indeed, the
most common mutated gene is FRDA, but mutations in
SACS, POLG, APTX, SYNE1 are also some other gene that
can be mutated and cause cerebellar ataxia. Obviously, the
presence of specific symptoms can help the clinician to
find the proper diagnosis, but it can also become a night-
mare. While a whole exome sequencing (WES) approach
has been proven to be powerful for the identification of
new disease causative genes, the same approach also
represents a rapid and efficient tools to screen known
genes for the presence of mutations [4]. In Canada, a
diagnostic tool using WES was used to diagnose early
onset ataxias [5].Case presentation
Index family: Our family was selected according the
FORGE criteria mainly for the presence of a clear reces-
sive mode of inheritance, an early age of onset and at
least two affected family members with Canadian ori-
gins. This family (Figure 1) was seen at two different
time point: for the first time in 2004 and later in 2012,
where they underwent clinical evaluation by a neurolo-
gist (ND). The proband of the family (arrow, Figure 1-A)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain

























Figure 1 Pedigree of index Family (A) associated with individual affection status and mutations segregation in the family (B).
Figure 2 Sagittal T1 sequence images revealed significant
cerebellar atrophy, especially in cerebral vermis in the
oldest son.
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came from the Quebec City and the mother from the
Portneuf region, and no consanguinity was known in this
family. In 2004, the first case (Figure 1, Individual II-1)
was 20 years of age, and was seen for one principal fea-
ture: upper limb tremor. This boy was born after a normal
pregnancy, normal delivery and with normal APGARS.
He walked for the first time at 15 months of age. He was
seen in neurology after some language problems that re-
sulted in the failure of his first year at school. At the first
neurological examination, the patient was complaining
of hand tremor which affected his fine dexterity. He also
presented with head tremor. He did not show any dysarth-
ria or ataxia. Magnetic brain imaging (MRI) revealed
cerebellar atrophy (Figure 2), localised at the cerebel-
lar hemispheres and the vermis. Her sister (Figure 1,
Individual II-2) was 10 years of age at the first neuro-
logical examination. Again, the mother reported a normal
pregnancy. She was seen early for global developmental
delay and hypotonia. She walked for the first time at 23
months of age, with the assistance of orthotics. She had a
surgery for alternating strabismus. At a young age, lan-
guage delay was noted, leading to the necessity to be
followed by a speech therapist and by an occupational
therapist. At school, she could never attend regular clas-
ses. MRI also revealed congenital atrophy of the cerebel-
lum, particularly at vermis. The European Federation of
Neurological Societies (EFNS) and European Neurological
Society (ENS) recently published guidelines for the
diagnosis and management of chronic ataxias [6]. Foran autosomal recessive mode of inheritance, found in our
family, the recommend a third-step diagnostic approach.
The first step is mutation analysis of the FRDA gene and
biochemical testing, the second step is mutation analysis
of SACS gene, POLG, APTX and SPG7 and the third step
is skin or muscle biopsy. In our family, we did mutation
analysis for only two most frequent gene known to cause
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SACS and FRDA testing were both negative. Lactic acid
and vitamin E levels were also normal. At 18 years old, the
most significant clinical features were hand tremor, dys-
arthria and dysphonia.
Given the growing number of genes involved in cere-
bellar ataxia, we decided to use a more global approach
by using new sequencing technologies. WES was per-
formed on the unaffected mother and two affected chil-
dren (Figure 1, Individuals I-2, II-2 and II-3). At first a
global analysis of sequence coverage was made (data not
shown). Hence it was clear that WES produced a good
coverage for each of the three individuals. We identi-
fied two mutations known to cause a rare disorder called
Congenital Disorder of Glycosylation, type Ia (CDG1A)
(OMIM #212065). This syndrome is caused by PMM2
mutations that create a deficiency of the phosphomanno-
mutase (PMM) enzyme which as a subsequent result lead
to defective synthesis of N-linked oligosaccharides. In our
family, the two affected siblings harbor compound het-
erozygote mutations: c.422G>A (p.R141H) and c.722G >C
(p.C241S) (Figure 1-B). The first mutation (c.422G > A)
(p.R141H) was also present in the unaffected sister and
this mutation was transmitted by the unaffected mother.
On the other hand, the second mutation c.722G > C
(p.C241S) was completely absent from the unaffected
sister and was clearly transmitted by the father. The two
mutations were confirmed by Sanger sequencing, in all in-
dividuals available in this family.
Conclusions
PMM2-CDG is the most common of a group of disor-
ders of abnormal glycosylation of N-linked oligosaccha-
rides. Clinical presentation and course of the disease are
highly variable, ranging from infants who die early to
mildly involved adults, which is the case for our family
[5]. In the infantile multisystem type, infants show axial
hypotonia, hyporeflexia, esotropia, developmental delay
and language is severely delayed. Hyperglycemia-induced
growth hormone release may occur [5], which might ex-
plain why the affected daughter is very tall. Some female
cases may also lack secondary sexual development [5],
which may explain why the affected daughter did not have
regular menstrual periods. Since the mutation p.C241A is
known to only partially affect the function of the PMM2
enzymes (reduction of activity by only 2 fold), therefore
it is in correlation with the mild presentation of the
two patients [7-9].
High-throughput sequencing technologies and WES
have enabled us to provide a clear genetic diagnosis to
explain the condition observed in this family. Given only
hand tremor and cerebellar ataxia were observed, it was
difficult to establish the exact genetic cause for the dis-
ease segregating in this family. With the availability ofWES results, the diagnosis became more obvious for the
neurologists who saw the patients. Mild ataxic clinical
phenotypes have previously been reported in CDG pa-
tients, where conventional biochemical analysis results
were false negative [10]. For this main reason, we sug-
gest to only perform WES for the diagnosis. Now, it will
be possible to better manage the condition of the af-
fected members and also to prevent or follow the onset
of other symptoms associated with this syndrome.
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